钇-90放射栓塞后肝移植:207例患者15年经验
该研究纳入2004至2018年间接受钇-90(Y90)放射栓塞后行肝移植的207例肝细胞癌(HCC)患者,评估长期结局。从肝移植起算的总生存期为12.5年,3年、5年、10年总生存率分别为84%、77%、60%;完全/广泛坏死者无复发生存优于部分坏死(P < 0.0001)。
要点
- Y90作为桥接或降期至肝移植的治疗有效,移植后中位总生存达12.5年。
- 完全或广泛肿瘤坏死患者无复发生存显著优于部分坏死(P < 0.0001)。
- 桥接与降期患者的总生存和无复发生存无差异。
核心结论
- Y90是HCC桥接或降期至肝移植的有效治疗,完全或广泛坏死与更好的无复发生存相关。
研究设计与样本
- 回顾性队列研究,纳入2004至2018年间接受Y90后行肝移植的207例HCC患者。
- 基线及移植前按UNOS TNM标准分期,记录Y90后毒性和移植物病理。
- 采用Kaplan-Meier估计终点时间,log-rank检验和Cox比例风险模型进行单多因素分析。
主要发现
- 从肝移植起算的总生存期为12.5年,至肝移植中位时间7.5个月(四分位距4.4-10.3)。
- 169例为桥接,38例为降期至肝移植。
- 病理示完全坏死94例(45%)、广泛坏死60例(29%)、部分坏死53例(26%)。
- 3年、5年、10年总生存率分别为84%、77%、60%。
临床怎么用
- Y90可作为HCC患者桥接或降期至肝移植的新辅助治疗选择。
- 治疗后达到完全或广泛坏死提示更优的无复发生存,支持术前新辅助治疗实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Radioembolization (yttrium-90 [Y90]) is used in hepatocellular carcinoma (HCC) as a bridging as well as downstaging liver-directed therapy to curative liver transplantation (LT). In this study, we report long-term outcomes of LT for patients with HCC who were bridged/downstaged by Y90. APPROACH AND RESULTS: Patients undergoing LT following Y90 between 2004 and 2018 were included, with staging by United Network for Organ Sharing (UNOS) tumor-node-metastasis criteria at baseline pre-Y90 and pre-LT. Post-Y90 toxicities were recorded. Histopathological data of HCC at explant were recorded. Long-term outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-specific mortality (DSM), and time-to-recurrence, were reported. Time-to-endpoint analyses were estimated using Kaplan-Meier. Univariate and multivariate analyses were performed using a log-rank test and Cox proportional-hazards model, respectively. During the 15-year period, 207 patients underwent LT after Y90. OS from LT was 12.5 years, with a median time to LT of 7.5 months [interquartile range, 4.4-10.3]. A total of 169 patients were bridged, whereas 38 were downstaged to LT. Respectively, 94 (45%), 60 (29%), and 53 (26%) patients showed complete, extensive, and partial tumor necrosis on histopathology. Three-year, 5-year, and 10-year OS rates were 84%, 77%, and 60%, respectively. Twenty-four patients developed recurrence, with a median RFS of 120 (95% confidence interval, 69-150) months. DSM at 3, 5, and 10 years was 6%, 11%, and 16%, respectively. There were no differences in OS/RFS for patients who were bridged or downstaged. RFS was higher in patients with complete/extensive versus partial tumor necrosis (P < 0.0001). For patients with UNOS T2 treated during the study period, 5.2% dropped out because of disease progression. CONCLUSIONS: Y90 is an effective treatment for HCC in the setting of bridging/downstaging to LT. Patients who achieved extensive or complete necrosis had better RFS, supporting the practice of neoadjuvant treatment before LT.
引用
- Gabr A, Kulik L, Mouli S, et al. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology. 2020. PMID: 32416631. doi:10.1002/hep.31318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。